Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer.

Walker AK, Karaszi K, Valentine H, Strauss VY, Choudhury A, McGill S, Wen K, Brown MD, Ramani V, Bhattarai S, Teo MTW, Yang L, Myers KA, Deshmukh N, Denley H, Browning L, Love SB, Iyer G, Clarke NW, Hall E, Huddart R, James ND, Hoskin PJ, West CML, Kiltie AE.

Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):809-818. doi: 10.1016/j.ijrobp.2019.03.015. Epub 2019 Mar 15.

2.

Phase 2 Neoadjuvant Treatment Intensification Trials in Rectal Cancer: A Systematic Review.

Teo MTW, McParland L, Appelt AL, Sebag-Montefiore D.

Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):146-158. doi: 10.1016/j.ijrobp.2017.09.042. Epub 2017 Sep 29. Review.

3.

Impact of prophylactic gastrostomy or reactive NG tube upon patient-reported long term swallow function following chemoradiotherapy for oropharyngeal carcinoma: A matched pair analysis.

Sethugavalar B, Teo MT, Buchan C, Ermiş E, Williams GF, Sen M, Prestwich RJD.

Oral Oncol. 2016 Aug;59:80-85. doi: 10.1016/j.oraloncology.2016.06.007.

PMID:
27424186
4.

Prevention and Management of Radiation-induced Late Gastrointestinal Toxicity.

Teo MT, Sebag-Montefiore D, Donnellan CF.

Clin Oncol (R Coll Radiol). 2015 Nov;27(11):656-67. doi: 10.1016/j.clon.2015.06.010. Epub 2015 Jun 28. Review.

5.

Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer.

Rafnar T, Sulem P, Thorleifsson G, Vermeulen SH, Helgason H, Saemundsdottir J, Gudjonsson SA, Sigurdsson A, Stacey SN, Gudmundsson J, Johannsdottir H, Alexiusdottir K, Petursdottir V, Nikulasson S, Geirsson G, Jonsson T, Aben KK, Grotenhuis AJ, Verhaegh GW, Dudek AM, Witjes JA, van der Heijden AG, Vrieling A, Galesloot TE, De Juan A, Panadero A, Rivera F, Hurst C, Bishop DT, Sak SC, Choudhury A, Teo MT, Arici C, Carta A, Toninelli E, de Verdier P, Rudnai P, Gurzau E, Koppova K, van der Keur KA, Lurkin I, Goossens M, Kellen E, Guarrera S, Russo A, Critelli R, Sacerdote C, Vineis P, Krucker C, Zeegers MP, Gerullis H, Ovsiannikov D, Volkert F, Hengstler JG, Selinski S, Magnusson OT, Masson G, Kong A, Gudbjartsson D, Lindblom A, Zwarthoff E, Porru S, Golka K, Buntinx F, Matullo G, Kumar R, Mayordomo JI, Steineck DG, Kiltie AE, Jonsson E, Radvanyi F, Knowles MA, Thorsteinsdottir U, Kiemeney LA, Stefansson K.

Hum Mol Genet. 2014 Oct 15;23(20):5545-57. doi: 10.1093/hmg/ddu264. Epub 2014 May 26.

6.

Post-transcriptional regulation of MRE11 expression in muscle-invasive bladder tumours.

Martin RM, Kerr M, Teo MT, Jevons SJ, Koritzinsky M, Wouters BG, Bhattarai S, Kiltie AE.

Oncotarget. 2014 Feb 28;5(4):993-1003.

7.

Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer.

Teo MT, Dyrskjøt L, Nsengimana J, Buchwald C, Snowden H, Morgan J, Jensen JB, Knowles MA, Taylor G, Barrett JH, Borre M, Orntoft TF, Bishop DT, Kiltie AE.

Ann Oncol. 2014 Apr;25(4):877-83. doi: 10.1093/annonc/mdu014. Epub 2014 Mar 12.

8.

Long-term swallow function after chemoradiotherapy for oropharyngeal cancer: the influence of a prophylactic gastrostomy or reactive nasogastric tube.

Prestwich RJ, Teo MT, Gilbert A, Williams G, Dyker KE, Sen M.

Clin Oncol (R Coll Radiol). 2014 Feb;26(2):103-9. doi: 10.1016/j.clon.2013.10.005. Epub 2013 Nov 15.

9.

Imatinib radiosensitizes bladder cancer by targeting homologous recombination.

Qiao B, Kerr M, Groselj B, Teo MT, Knowles MA, Bristow RG, Phillips RM, Kiltie AE.

Cancer Res. 2013 Mar 1;73(5):1611-20. doi: 10.1158/0008-5472.CAN-12-1170. Epub 2013 Jan 9.

10.

Enteral feeding outcomes after chemoradiotherapy for oropharynx cancer: a role for a prophylactic gastrostomy?

Williams GF, Teo MT, Sen M, Dyker KE, Coyle C, Prestwich RJ.

Oral Oncol. 2012 May;48(5):434-40. doi: 10.1016/j.oraloncology.2011.11.022. Epub 2011 Dec 29.

PMID:
22209648
11.

The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes.

Teo MT, Landi D, Taylor CF, Elliott F, Vaslin L, Cox DG, Hall J, Landi S, Bishop DT, Kiltie AE.

Carcinogenesis. 2012 Mar;33(3):581-6. doi: 10.1093/carcin/bgr300. Epub 2011 Dec 12.

12.

Quantitative neuroproteomics of an in vivo rodent model of focal cerebral ischemia/reperfusion injury reveals a temporal regulation of novel pathophysiological molecular markers.

Datta A, Jingru Q, Khor TH, Teo MT, Heese K, Sze SK.

J Proteome Res. 2011 Nov 4;10(11):5199-213. doi: 10.1021/pr200673y. Epub 2011 Oct 20.

PMID:
21950801
13.

In vitro functional effects of XPC gene rare variants from bladder cancer patients.

Qiao B, Ansari AH, Scott GB, Sak SC, Chambers PA, Elliott F, Teo MT, Bentley J, Churchman M, Hall J, Taylor CF, Bishop TD, Knowles MA, Kiltie AE.

Carcinogenesis. 2011 Apr;32(4):516-21. doi: 10.1093/carcin/bgr005. Epub 2011 Jan 27.

14.

A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci.

Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD, Real FX, Van Den Berg D, Matullo G, Baris D, Thun M, Kiemeney LA, Vineis P, De Vivo I, Albanes D, Purdue MP, Rafnar T, Hildebrandt MA, Kiltie AE, Cussenot O, Golka K, Kumar R, Taylor JA, Mayordomo JI, Jacobs KB, Kogevinas M, Hutchinson A, Wang Z, Fu YP, Prokunina-Olsson L, Burdett L, Yeager M, Wheeler W, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G Jr, Grubb R 3rd, Black A, Jacobs EJ, Diver WR, Gapstur SM, Weinstein SJ, Virtamo J, Cortessis VK, Gago-Dominguez M, Pike MC, Stern MC, Yuan JM, Hunter DJ, McGrath M, Dinney CP, Czerniak B, Chen M, Yang H, Vermeulen SH, Aben KK, Witjes JA, Makkinje RR, Sulem P, Besenbacher S, Stefansson K, Riboli E, Brennan P, Panico S, Navarro C, Allen NE, Bueno-de-Mesquita HB, Trichopoulos D, Caporaso N, Landi MT, Canzian F, Ljungberg B, Tjonneland A, Clavel-Chapelon F, Bishop DT, Teo MT, Knowles MA, Guarrera S, Polidoro S, Ricceri F, Sacerdote C, Allione A, Cancel-Tassin G, Selinski S, Hengstler JG, Dietrich H, Fletcher T, Rudnai P, Gurzau E, Koppova K, Bolick SC, Godfrey A, Xu Z, Sanz-Velez JI, D García-Prats M, Sanchez M, Valdivia G, Porru S, Benhamou S, Hoover RN, Fraumeni JF Jr, Silverman DT, Chanock SJ.

Nat Genet. 2010 Nov;42(11):978-84. doi: 10.1038/ng.687. Epub 2010 Oct 24.

15.

MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer.

Choudhury A, Nelson LD, Teo MT, Chilka S, Bhattarai S, Johnston CF, Elliott F, Lowery J, Taylor CF, Churchman M, Bentley J, Knowles MA, Harnden P, Bristow RG, Bishop DT, Kiltie AE.

Cancer Res. 2010 Sep 15;70(18):7017-26. doi: 10.1158/0008-5472.CAN-10-1202.

Supplemental Content

Support Center